Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

PROT recently reported that it has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity. X Gen Medical has been established with the intention of conducting business in the global medical marketplace.

Proteonomix plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide.

It is anticipated that new relationships formed with X Gen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism. Medical tourism is constantly on the rise and anticipated to continue to grow substantially due to current high costs of health care for certain procedures and improvements in both technology and standards of care in many countries.

For more information about this company please visit http://www.proteonomix.com

Tiens Biotech Group USA, Inc. (AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements.

TBV derives its revenues principally from product sales to affiliated companies in China and internationally in 54 countries.

Since its establishment, Tiens has developed and produced 37 nutrition supplements, which include wellness products and dietary supplements.

Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry.

Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

For more information about this company please visit http://www.tiens-bio.com

Trinity Biotech plc (NASDAQ: TRIB) is a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets.

TRIB recently reported results for the quarter ended June 30, 2010.

During the quarter the company recognised a profit on the sale of its coagulation product line of $47.4m. This reflects the sales proceeds of $90m less the carrying value of the assets divested and associated costs. This is partly offset by a once-off charge of $0.3m in relation to the restructuring of the company's HIV manufacturing activities, which will result in improved profitability from early 2011
onwards.

Operating profit decreased from $3.8m in quarter 2, 2009 to $3.5m in the current quarter due to the coagulation divestiture. However, the operating margin for the quarter has increased to 15.5% which represents a significant improvement compared to 11.9% in quarter 2, 2009.

For more information about this company please visit http://www.trinitybiotech.com

CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup

PLEASE BE SURE TO VISIT CRWESELECT.NING.COM

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more). Rule 17B of the Securities Act of 1933 requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

PROTcrweselect0807